In today's edition of Market Checkup, health-care analysts David Williamson and Max Macaluso take a close look at Onyx Pharmaceuticals, which may or may not be acquired in the coming weeks, and Eli Lilly, which recently announced positive clinical trial results for an experimental cancer drug.
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
The Motley Fool's health-care show, "Market Checkup," for August 15, 2013.
About the Author
Max is the Technology, Biopharma & Health Care Bureau Chief at Fool.com. Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.
David Williamson owns shares of Pfizer. Max Macaluso, Ph.D. owns shares of Celgene. The Motley Fool recommends Celgene. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Related Articles
Why Atai Life Sciences Stock Was So Lively This Week
Better Beaten-Down Stock: Iovance Biotherapeutics vs. Teladoc Health
2 Soaring Cathie Wood Stocks to Buy and Hold
Eli Lilly vs. Viking Therapeutics Stock: Which Is the Best Growth Opportunity, According to Wall Street?
Why Grail Stock Soared 14% Higher on Thursday
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.